US FDA's data falsification rule raises industry concerns
This article was originally published in Clinica
Executive Summary
The US medtech industry has expressed serious concerns about a new rule proposed by the FDA, which, if finalised, would require device sponsors to report to the agency about any individual who is suspected of falsifying data in studies involving human or animal subjects.